drugset / Trial / NCT00491192
Normothermia in Patients With Acute Cerebral Damage
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of our study is to verify wherever normothermia (achieved with diclofenac administration) may improve intracranial pressure control and may limit secondary cerebral damage thus positively influencing outcome in patients with acute cerebral damage admitted to ICU.
Timeline
- Start
- 2007-06
- Primary completion
- —
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Diclofenac | Other / unclassified | 0.35 mg/kg | Subcutaneous |
| Subject | Diclofenac | Other / unclassified | 0.48 mg/kg | Subcutaneous |
| Subject | Diclofenac | Other / unclassified | 0.5 mg/kg | Subcutaneous |